Premium
Treatment of idiopathic oligozoospermia with combined human chorionic gonadotropin/human menopausal gonadotrophin: A randomised, double‐blinded, placebo‐controlled clinical study
Author(s) -
Zhao Nan,
Lu XiLan,
Li JunTao,
Zhang JianMin
Publication year - 2019
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.13271
Subject(s) - andrology , spermatid , dna fragmentation , human chorionic gonadotropin , male infertility , sperm , placebo , pregnancy rate , semen , medicine , population , testicular sperm extraction , gonadotropin , gynecology , intracytoplasmic sperm injection , infertility , urology , biology , pregnancy , hormone , pathology , apoptosis , biochemistry , genetics , alternative medicine , environmental health , programmed cell death
To evaluate whether hCG/hMG therapy has beneficial effects on idiopathic oligozoospermia in Chinese infertility population. The patients were randomly divided into the treatment group receiving hCG/hMG for 3 months and the placebo group receiving placebo for 3 months. Semen and biochemical analysis was performed, and DNA fragmentation as well as spermatid concentration was evaluated. Administration of hCG/hMG for 3 months could significantly improve sperm concentration, rate of forward motile spermatozoa, total motile sperm count, the percentage of sperm with normal morphology and the rate of spontaneous pregnancy in medium‐ and higher‐level inhibin B group respectively. Moreover, in medium‐ and higher‐level inhibin B group, sperm DNA fragmentation index and spermatid concentration were significantly declined respectively at the end of treatment. However, there were no significant differences in lower‐level inhibin B group before and after treatment in term of seminal parameters, DNA fragmentation and spermatid concentration. HCG/hMG therapy for 3 months has a beneficial effect on a part of male with idiopathic oligozoospermia, and the efficacy of hCG/hMG therapy is associated with the inhibin B level.